How does TCR cell therapy differ from CAR T-cell therapy regarding antigen recognition?
Answer
TCR therapy recognizes antigens processed inside the cell and presented via HLA
The core difference between these two therapies lies in where they look for their targets. While CAR T-cells are designed to scan and bind to antigens directly on the exterior membrane of cancer cells, TCR cell therapy is engineered to identify antigens that have been processed inside the cancer cell and presented on the surface via the Human Leukocyte Antigen or HLA complex. This mechanism allows TCR therapy to address targets located within the cell, potentially expanding the range of treatable cancers, particularly solid tumors.
Related Questions
What is the defining characteristic of CAR T-cell therapy?Which protein serves as the common target for CAR T-cell therapy in B-cell cancers?What is the primary function of the leukapheresis procedure?What role does a vector derived from a deactivated virus play in T-cell engineering?How does TCR cell therapy differ from CAR T-cell therapy regarding antigen recognition?What triggers the onset of Cytokine Release Syndrome or CRS?What distinguishes neurotoxicity or ICANS from other CAR T-cell therapy side effects?What is the purpose of bridging chemotherapy during the waiting period?What defines the expansion phase in the CAR T-cell manufacturing protocol?What is the intended advantage of developing off-the-shelf allogeneic products?